In Brief: Abbott's Biaxin
Abbott's Biaxin: Supplemental NDA submitted for Biaxin for prevention of disseminated Mycobacterium avium complex disease in advanced HIV, the company announces May 30. Biaxin (clarithromycin) was given accelerated approval in December 1993 for treatment of MAC. A two-year, double-blind study of 682 patients randomized to either 500 mg clarithromycin or placebo twice daily found the incidence of disseminated MAC was reduced 69% with prophylactic Biaxin use. Mortality from all causes was reduced by 28% ("The Pink Sheet" Oct. 10, 1994, T&G-10)...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth